Клональная эволюция при острых миелоидных лейкозах: современные представления и собственные наблюдения

Введение. Острый миелоидный лейкоз (ОМЛ) характеризуется сложной клональной структурой, формирующейся в результате клональной эволюции. Изучение клональной эволюции продиктовано необходимостью повышения эффективности терапевтических стратегий ОМЛ.

Цель: обобщить представление о клональной эволюции ОМЛ и показать клональную эволюцию в условиях реальной клинической практики на примере 3 клинических наблюдений.

Основные сведения. Представлено описание клинических наблюдений клональной эволюции ОМЛ у 3 больных с впервые выявленным ОМЛ. Молекулярно-генетический анализ генов FLT3 и NPM1 выполнили с использованием коммерческих наборов. Рассмотрены основные модели клональной эволюции ОМЛ: линейная и ветвящаяся. Представлены данные изучения лейкозных стволовых клеток. Клональная эволюция показана на примере 3 клинических наблюдений, даны разъяснения и рекомендации по подбору терапии. Клональная эволюция ОМЛ представляет собой длительный и непрерывный процесс, в результате которого складывается сложноветвящийся паттерн молекулярно-генетических поломок с участием стволовой лейкозной клетки. В этой связи на всех этапах развития ОМЛ (дебют, ремиссия, рецидив) необходимо диагностировать максимальное число молекулярно-генетических маркеров. Лечение с учетом знания закономерностей клональной эволюции позволит повысить эффективность терапии.

1. Meyers J., Yu Y., Kaye J.A., et al. Medicare Fee-for-Service Enrollees with Primary Acute Myeloid Leukemia: An Analysis of Treatment Patterns, Survival, and Healthcare Resource Utilization and Costs. Appl Health Econ Health Policy. 2013;11:275–86. DOI: 10.1007/s40258-013-0032-2.

2. Herold T., Rothenberg-Thurley M., Grunwald V.V., et al. Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. Leukemia. 2020;34:3161–72. DOI: 10.1038/s41375-020-0806-0.

3. Estey E. Acute myeloid leukemia: 2016 Update on risk-stratification and management. Am J Hematol. 2016;91:824–46. DOI: DOI:10.1002/ajh.24439.

4. Maher K.R., Murray G.F., Ho T., et al. Toward a Deeper Understanding of Clonal Evolution in Acute Myeloid Leukemia: Translational and Clinical Impacts. J Cell Signal. 2025;6:48–52. DOI: 10.33696/Signaling.6.133.

5. Steensma D.P., Bejar R., Jaiswal S., et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015;126:9– 16. DOI: 10.1182/blood-2015-03-631747.

6. Genovese G., Kähler A.K., Handsaker R.E., et al. Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence. N Engl J Med. 2014;371:2477–87. DOI: 10.1056/nejmoa1409405.

7. Jaiswal S., Natarajan P., Silver A.J., et al. Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. N Engl J Med. 2017;377:111–21. DOI: 10.1056/nejmoa1701719.

8. Cremer S., Kirschbaum K., Berkowitsch A., et al. Multiple Somatic Mutations for Clonal Hematopoiesis Are Associated With Increased Mortality in Patients With Chronic Heart Failure. Circ Genom Precis Med. 2020;13:e003003. DOI: 10.1161/CIRCGEN.120.003003.

9. Xie M., Lu C., Wang J., et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med. 2014;20:1472–8. DOI: 10.1038/nm.3733.

10. Shlush L.I. Age-related clonal hematopoiesis. Blood. 2018;131:496–504. DOI: 10.1182/blood-2017-07-746453.

11. Khoury J.D., Solary E., Abla O., et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36:1703–19. DOI: 10.1038/s41375-022-01613-1.

12. Corces M.R., Chang H.Y., Majeti R. Preleukemic Hematopoietic Stem Cells in Human Acute Myeloid Leukemia. Front Oncol. 2017;7:263. DOI: 10.3389/fonc.2017.00263.

13. Majeti R., Becker M.W., Tian Q., et al. Dysregulated gene expression networks in human acute myelogenous leukemia stem cells. Proc Natl Acad Sci. 2009;106:3396–401. DOI: 10.1073/pnas.0900089106.

14. Jan M., Snyder T.M., Corces-Zimmerman M.R., et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci Transl Med. 2012;4:149ra118. DOI: 10.1126/scitranslmed.3004315.

15. Chen J., Kao Y-R., Sun D., et al. Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level. Nat Med. 2019;25:103–10. DOI: 10.1038/s41591-018-0267-4.

16. Stauber J., Greally J.M., Steidl U. Preleukemic and leukemic evolution at the stem cell level. Blood. 2021;137:1013–8. DOI: 10.1182/blood.2019004397.

17. Shin D-Y. Human acute myeloid leukemia stem cells: evolution of concept. Blood Res. 2022;57:S67–74. DOI: 10.5045/br.2022.2021221.

18. Sturgeon C.M., Wagenblast E., Izzo F., et al. The Crossroads of Clonal Evolution, Differentiation Hierarchy, and Ontogeny in Leukemia Development. Blood Cancer Discov. 2025;6:94–109. DOI: 10.1158/2643-3230.BCD-24-0235.

19. Lapidot T., Sirard C., Vormoor J., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367:645–8. DOI: 10.1038/367645a0.

20. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730–7. DOI: 10.1038/nm0797-730.

21. Kreso A., Dick J.E. Evolution of the Cancer Stem Cell Model. Cell Stem Cell. 2014;14:275–91. DOI: 10.1016/j.stem.2014.02.006.

22. Clarke M.F., Dick J.E., Dirks P.B., et al. Cancer Stem Cells—Perspectives on Current Status and Future Directions: AACR Workshop on Cancer Stem Cells. Cancer Res. 2006;66:9339–44. DOI: 10.1158/0008-5472.CAN-06-3126.

23. Klco J.M., Spencer D.H., Miller C.A., et al. Functional Heterogeneity of Genetically Defined Subclones in Acute Myeloid Leukemia. Cancer Cell. 2014;25:379– 92. DOI: 10.1016/j.ccr.2014.01.031.

24. Anderson K., Lutz C., van Delft F.W., et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature. 2011;469:356–61. DOI: 10.1038/nature09650.

25. Notta F., Mullighan C.G., Y.Wang J.C., et al. Erratum: Evolution of human BCR–ABL1 lymphoblastic leukaemia-initiating cells. Nature. 2011;471:254. DOI: 10.1038/nature09877.

26. Takahashi K., Tanaka T. Clonal evolution and hierarchy in myeloid malignancies. Trends Cancer. 2023;9:707–15. DOI: 10.1016/j.trecan.2023.05.004.

27. Shlush L.I., Zandi S., Mitchell A., et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature. 2014;506:328–33. DOI: 10.1038/nature13038.

28. Stauber J., Greally J.M., Steidl U. Preleukemic and leukemic evolution at the stem cell level. Blood. 2021;137(8):1013-1018. DOI: 10.1182/blood.2019004397.

29. Vardiman J.W., Thiele J., Arber D.A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51. DOI: 10.1182/blood-2009-03-209262.

30. Arber D.A., Orazi A., Hasserjian R., et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405. DOI: 10.1182/blood-2016-03-643544.

31. Döhner H., Wei A.H., Appelbaum F.R., et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345–77. DOI: 10.1182/blood.2022016867.

32. Döhner H., Estey E.H., Amadori S., et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453–74. DOI: 10.1182/blood-2009-07-235358.

33. Döhner H., Estey E., Grimwade D., et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47. DOI: 10.1182/blood-2016-08-733196.

34. Döhner H., Weisdorf D.J., Bloomfield C.D. Acute Myeloid Leukemia. N Engl J Med. 2015;373:1136–52. DOI: 10.1056/NEJMra1406184.

35. Falini B., Mecucci C., Tiacci E., et al. Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype. N Engl J Med.2005;352:254– 66. DOI: 10.1056/NEJMoa041974.

36. Cocciardi S., Dolnik A., Kapp-Schwoerer S., et al. Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation. Nat Commun. 2019;10:2031. DOI: 10.1038/s41467-019-09745-2.

37. Krönke J., Bullinger L., Teleanu V., et al. Clonal evolution in relapsed NPM1- mutated acute myeloid leukemia. Blood. 2013;122:100–8. DOI: 10.1182/blood-2013-01-479188.

38. Höllein A., Meggendorfer M., Dicker F., et al. NPM1 mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapse. Blood Adv. 2018;2:3118–25. DOI: 10.1182/bloodadvances.2018023432.

39. Daver N., Schlenk R.F., Russell N.H., et al. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33:299–312. DOI: 10.1038/s41375-018-0357-9.

40. Thiede C., Steudel C., Mohr B., et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis: Presented in part at the 42nd Annual Meeting of the American Society of Hematology, December 1-5, 2000, San Francisco, CA (abstract 2334). Blood. 2002;99:4326–35. DOI: 10.1182/blood.V99.12.4326.

41. Metzeler K.H., Herold T., Rothenberg-Thurley M., et al. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. Blood. 2016;128:686–98. DOI: 10.1182/blood-2016-01-693879.

42. Levis M. FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013? Hematology Am Soc Hematol Educ Program. 2013;2013:220–6. DOI: 10.1182/asheducation-2013.1.220.

43. Nagel G., Weber D., Fromm E., et al. Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO). Ann Hematol. 2017;96:1993–2003. DOI: 10.1007/s00277-017-3150-3.

44. Gilliland D.G., Griffin J.D. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100:1532–42. DOI: 10.1182/blood-2002-02-0492.

45. Gu T., Nardone J., Wang Y., et al. Survey of Activated FLT3 Signaling in Leukemia. PLoS One. 2011;6:e19169.

46. Tao S., Wang C., Chen Y., et al. Prognosis and outcome of patients with acute myeloid leukemia based on FLT3-ITD mutation with or without additional abnormal cytogenetics. Oncol Lett. 2019:6766–74. DOI: 10.3892/ol.2019.11051.

47. Bacher U., Haferlach C., Kern W., et al. Prognostic relevance of FLT3-TKD mutations in AML: the combination matters—an analysis of 3082 patients. Blood. 2008;111:2527–37. DOI: 10.1182/blood-2007-05-091215.

48. Ke Y-Y., Singh V.K., Coumar M.S., et al. Homology modeling of DFG-in FMSlike tyrosine kinase 3 (FLT3) and structure-based virtual screening for inhibitor identification. Sci Rep. 2015;5:11702. DOI: 10.1038/srep11702.

49. Larrosa-Garcia M.., Baer M.R. FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions. Mol Cancer Ther. 2017;16:991–1001. DOI: 10.1158/1535-7163.MCT-16-0876.

50. Паровичникова Е. Н. Национальные клинические рекомендации по диагностике и лечению острых миелоидных лейкозов взрослых. Национальное гематологическое общество 2024.

51. Smith C.C., Paguirigan A., Jeschke G.R., et al. Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis. Blood. 2017;130:48–58. DOI: 10.1182/blood-2016-04-711820.

52. Zhang H, Savage S, Schultz AR, et al. Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms. Nat Commun. 2019;10:244. DOI: 10.1038/s41467-018-08263-x.

53. Heidel F., Solem F.K., Breitenbuecher F., et al. Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. Blood. 2006;107:293–300. DOI: 10.1182/blood-2005-06-2469.

54. Smith C.C., Wang Q., Chin C-S., et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature. 2012;485:260–3. DOI: 10.1038/nature11016.

55. Biavasco F., Zeiser R. FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation. Int J Hematol. 2022;116:341–50. DOI: 10.1007/s12185-022-03352-6.

56. Tiesmeier J., Müller-Tidow C., Westermann A., et al. Evolution of FLT3-ITD and D835 activating point mutations in relapsing acute myeloid leukemia and response to salvage therapy. Leuk Res. 2004;28:1069–74. DOI: 10.1016/j.leukres.2004.02.009.

57. Warren M., Luthra R., Yin C.C., et al. Clinical impact of change of FLT3 mutation status in acute myeloid leukemia patients. Mod Pathol. 2012;25:1405–12. DOI: 10.1038/modpathol.2012.88.

58. Wattad M., Weber D., Döhner K., et al. Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure. Leukemia. 2017;31:1306–13. DOI: 10.1038/leu.2017.23.

59. Bibault J-E., Figeac M., Hélevaut N., et al. Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia. Oncotarget 2015;6:22812–21. DOI: 10.18632/oncotarget.4333.

60. Шатилова А.А., Будаева И.Г., Прокопьев И.Е. Гилтеритиниб — новая возможность в лечении рецидивов и рефрактерных острых миелоидных лейкозов с мутацией в гене FLT3: обзор литературы и описание трех собственных клинических наблюдений. Клиническая oнкогематология. 2023;16:69–79. DOI: 10.21320/2500-2139-2023-16-1-69-79.